{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T02:16:40Z","timestamp":1783304200340,"version":"3.54.6"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Suzhou Science and Technology Foundation for Young","award":["KJXW2023062"],"award-info":[{"award-number":["KJXW2023062"]}]},{"name":"Zhangjiagang Youth Science and Technology","award":["ZJGQNKJ202306"],"award-info":[{"award-number":["ZJGQNKJ202306"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82272687"],"award-info":[{"award-number":["82272687"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-51753-y","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T17:34:09Z","timestamp":1778002449000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mechanistic study of TIMM44 mediating gastric carcinogenesis via the G\u03b1i1-PI3K-AKT-mTOR signaling pathway"],"prefix":"10.1038","volume":"16","author":[{"given":"Ting","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongliang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"issue":"1","key":"51753_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73 (1), 17\u201348 (2023).","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"51753_CR2","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 72 (1), 7\u201333 (2022).","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"51753_CR3","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","volume":"135","author":"C Xia","year":"2022","unstructured":"Xia, C. et al. Cancer statistics in China and United States, 2022: Profiles, trends, and determinants. Chin. Med. J. (Engl) 135(5), 584\u2013590 (2022).","journal-title":"Chin. Med. J. (Engl)"},{"issue":"12","key":"51753_CR4","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/j.annonc.2021.08.1752","volume":"32","author":"T Yoshino","year":"2021","unstructured":"Yoshino, T. et al. Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. Ann. Oncol. 32(12), 1496\u20131510 (2021).","journal-title":"Ann. Oncol."},{"issue":"2","key":"51753_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani, J. A. et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc Netw. 20 (2), 167\u2013192 (2022).","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"10251","key":"51753_CR6","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth, E. C., Nilsson, M., Grabsch, H. I., van Grieken, N. C. & Lordick, F. Gastric cancer. Lancet 396(10251), 635\u2013648 (2020).","journal-title":"Lancet"},{"issue":"11","key":"51753_CR7","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/nrclinonc.2013.170","volume":"10","author":"R Wadhwa","year":"2013","unstructured":"Wadhwa, R. et al. Gastric cancer-molecular and clinical dimensions. Nat. Rev. Clin. Oncol. 10(11), 643\u2013655 (2013).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"68","key":"51753_CR8","doi-asserted-by":"publisher","first-page":"ra17","DOI":"10.1126\/scisignal.2000118","volume":"2","author":"C Cao","year":"2009","unstructured":"Cao, C. et al. Galpha(i1) and Galpha(i3) are required for epidermal growth factor-mediated activation of the Akt-mTORC1 pathway. Sci. Signal. 2 (68), ra17 (2009).","journal-title":"Sci. Signal."},{"issue":"7","key":"51753_CR9","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.7150\/thno.80749","volume":"13","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. G\u03b1i1\/3 mediate Netrin-1-CD146-activated signaling and angiogenesis. Theranostics 13 (7), 2319\u20132336 (2023).","journal-title":"Theranostics"},{"issue":"17","key":"51753_CR10","doi-asserted-by":"publisher","first-page":"4695","DOI":"10.7150\/thno.26203","volume":"8","author":"J Sun","year":"2018","unstructured":"Sun, J. et al. G\u03b1i1 and G\u03b1i3mediate VEGF-induced VEGFR2 endocytosis, signaling and angiogenesis. Theranostics 8 (17), 4695\u20134709 (2018).","journal-title":"Theranostics"},{"issue":"22","key":"51753_CR11","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.1038\/s41388-021-01812-7","volume":"40","author":"Y Lv","year":"2021","unstructured":"Lv, Y. et al. LncRNA PINK1-AS promotes G\u03b1i1-driven gastric cancer tumorigenesis by sponging microRNA-200a. Oncogene 40 (22), 3826\u20133844 (2021).","journal-title":"Oncogene"},{"issue":"17","key":"51753_CR12","doi-asserted-by":"publisher","first-page":"7586","DOI":"10.7150\/thno.78616","volume":"12","author":"YZ Guo","year":"2022","unstructured":"Guo, Y. Z. et al. TIMM44 is a potential therapeutic target of human glioma. Theranostics 12(17), 7586\u20137602 (2022).","journal-title":"Theranostics"},{"issue":"4","key":"51753_CR13","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s12013-020-00939-w","volume":"78","author":"X Yu","year":"2020","unstructured":"Yu, X. et al. HuR promotes ovarian cancer cell proliferation by regulating TIMM44 mRNA stability. Cell. Biochem. Biophys. 78(4), 447\u2013453 (2020).","journal-title":"Cell. Biochem. Biophys."},{"issue":"11","key":"51753_CR14","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/sj.bjc.6603455","volume":"95","author":"E Bonora","year":"2006","unstructured":"Bonora, E., Evangelisti, C., Bonichon, F., Tallini, G. & Romeo, G. Novel germline variants identified in the inner mitochondrial membrane transporter TIMM44 and their role in predisposition to oncocytic thyroid carcinomas. Br. J. Cancer 95(11), 1529\u20131536 (2006).","journal-title":"Br. J. Cancer"},{"issue":"5","key":"51753_CR15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41419-023-05826-9","volume":"14","author":"ZR Ma","year":"2023","unstructured":"Ma, Z. R. et al. The mitochondrial protein TIMM44 is required for angiogenesis in vitro and in vivo. Cell. Death Dis. 14 (5), 307 (2023).","journal-title":"Cell. Death Dis."},{"issue":"3","key":"51753_CR16","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3892\/ijo.2017.4067","volume":"51","author":"BG Ha","year":"2017","unstructured":"Ha, B. G., Jung, S. S. & Shon, Y. H. Effects of proton beam irradiation on mitochondrial biogenesis in a human colorectal adenocarcinoma cell line. Int. J. Oncol. 51(3), 859\u2013866 (2017).","journal-title":"Int. J. Oncol."},{"issue":"13","key":"51753_CR17","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1093\/hmg\/ddab116","volume":"30","author":"BC Lin","year":"2021","unstructured":"Lin, B. C. et al. ALS\/FTD mutations in UBQLN2 are linked to mitochondrial dysfunction through loss-of-function in mitochondrial protein import. Hum. Mol. Genet. 30(13), 1230\u20131246 (2021).","journal-title":"Hum. Mol. Genet."},{"key":"51753_CR18","volume":"56","author":"K Huang","year":"2025","unstructured":"Huang, K. et al. Early diagnosis of acute myocardial infarction via hub genes identified by integrated weighted gene co-expression network analysis. Am. Heart J. Plus. 56, 100554 (2025).","journal-title":"Am. Heart J. Plus."},{"issue":"2","key":"51753_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s12031-025-02340-9","volume":"75","author":"F Anjum","year":"2025","unstructured":"Anjum, F. et al. Discovering Novel Biomarkers and Potential Therapeutic Targets of Amyotrophic Lateral Sclerosis Through Integrated Machine Learning and Gene Expression Profiling. J. Mol. Neurosci. 75 (2), 61 (2025).","journal-title":"J. Mol. Neurosci."},{"issue":"5","key":"51753_CR20","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41571-023-00747-0","volume":"20","author":"AP Thrift","year":"2023","unstructured":"Thrift, A. P., Wenker, T. N. & El-Serag, H. B. Global burden of gastric cancer: Epidemiological trends, risk factors, screening and prevention. Nat. Rev. Clin. Oncol. 20(5), 338\u2013349 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"51753_CR21","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1200\/JCO.22.02331","volume":"41","author":"MA Shah","year":"2023","unstructured":"Shah, M. A. et al. Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO Guideline. J. Clin. Oncol. 41(7), 1470\u20131491 (2023).","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"51753_CR22","first-page":"264","volume":"71","author":"SS Joshi","year":"2021","unstructured":"Joshi, S. S. & Badgwell, B. D. Current treatment and recent progress in gastric cancer. CA. Cancer J. Clin. 71(3), 264\u2013279 (2021).","journal-title":"CA. Cancer J. Clin."},{"issue":"1","key":"51753_CR23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/nrclinonc.2013.231","volume":"11","author":"MA Shah","year":"2014","unstructured":"Shah, M. A. Gastrointestinal cancer: Targeted therapies in gastric cancer\u2014The dawn of a new era. Nat. Rev. Clin. Oncol. 11(1), 10\u201311 (2014).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"51753_CR24","first-page":"165","volume":"72","author":"P Tarantino","year":"2022","unstructured":"Tarantino, P. et al. Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. CA. Cancer J. Clin. 72(2), 165\u2013182 (2022).","journal-title":"CA. Cancer J. Clin."},{"issue":"25","key":"51753_CR25","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara, K. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl. J. Med. 382 (25), 2419\u20132430 (2020).","journal-title":"N Engl. J. Med."},{"issue":"9742","key":"51753_CR26","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376(9742), 687\u2013697 (2010).","journal-title":"Lancet"},{"issue":"5","key":"51753_CR27","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S1470-2045(17)30111-0","volume":"18","author":"PC Thuss-Patience","year":"2017","unstructured":"Thuss-Patience, P. C. et al. Trastuzumab Emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): An international randomised, open-label, adaptive, phase 2\/3 study. Lancet Oncol. 18(5), 640\u2013653 (2017).","journal-title":"Lancet Oncol."},{"issue":"5","key":"51753_CR28","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/nrclinonc.2016.53","volume":"13","author":"T Aoyama","year":"2016","unstructured":"Aoyama, T. & Yoshikawa, T. Targeted therapy: Apatinib - New third-line option for refractory gastric or GEJ cancer. Nat. Rev. Clin. Oncol. 13(5), 268\u2013270 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"13","key":"51753_CR29","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","volume":"34","author":"J Li","year":"2016","unstructured":"Li, J. et al. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J. Clin. Oncol. 34 (13), 1448\u20131454 (2016).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"51753_CR30","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12916-023-02841-7","volume":"21","author":"J Li","year":"2023","unstructured":"Li, J. et al. Safety and efficacy of Apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): A prospective, single-arm, multicenter, phase IV study. BMC Med. 21(1), 173. (2023).","journal-title":"BMC Med."},{"issue":"11","key":"51753_CR31","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke, H. et al. Ramucirumab plus Paclitaxel versus placebo plus Paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial. Lancet Oncol. 15(11), 1224\u20131235 (2014).","journal-title":"Lancet Oncol."},{"issue":"9911","key":"51753_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"Fuchs, C. S. et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383 (9911), 31\u201339 (2014).","journal-title":"Lancet"},{"issue":"3","key":"51753_CR33","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S1470-2045(18)30791-5","volume":"20","author":"CS Fuchs","year":"2019","unstructured":"Fuchs, C. S. et al. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 20 (3), 420\u2013435 (2019).","journal-title":"Lancet Oncol."},{"issue":"9","key":"51753_CR34","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1200\/JCO.20.02755","volume":"39","author":"MA Shah","year":"2021","unstructured":"Shah, M. A. et al. Phase III study to evaluate efficacy and safety of Andecaliximab with mFOLFOX6 as first-line treatment in patients with advanced gastric or GEJ adenocarcinoma (GAMMA-1). J. Clin. Oncol. 39(9), 990\u20131000 (2021).","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"51753_CR35","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: Phase 1 trial interim results. Nat. Med. 28(6), 1189\u20131198 (2022).","journal-title":"Nat. Med."},{"issue":"10111","key":"51753_CR36","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang, Y. K. et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390 (10111), 2461\u20132471 (2017).","journal-title":"Lancet"},{"issue":"2","key":"51753_CR37","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/annonc\/mdy540","volume":"30","author":"N Boku","year":"2019","unstructured":"Boku, N. et al. Safety and efficacy of Nivolumab in combination with S-1\/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric\/gastroesophageal junction cancer: Interim results of a randomized, phase II trial (ATTRACTION-4). Ann. Oncol. 30(2), 250\u2013258 (2019).","journal-title":"Ann. Oncol."},{"issue":"1","key":"51753_CR38","doi-asserted-by":"publisher","first-page":"2192098","DOI":"10.1080\/2162402X.2023.2192098","volume":"12","author":"O Kruglov","year":"2023","unstructured":"Kruglov, O. et al. Melanoma-associated repair-like Schwann cells suppress anti-tumor T-cells via 12\/15-LOX\/COX2-associated eicosanoid production. Oncoimmunology 12 (1), 2192098 (2023).","journal-title":"Oncoimmunology"},{"issue":"7","key":"51753_CR39","doi-asserted-by":"publisher","first-page":"10904","DOI":"10.1021\/acsnano.2c03222","volume":"16","author":"R Zhao","year":"2022","unstructured":"Zhao, R. et al. Dual glutathione depletion enhanced enzyme catalytic activity for hyperthermia assisted tumor therapy on semi-metallic VSe(2)\/Mn-CS. ACS Nano 16(7), 10904\u201310917 (2022).","journal-title":"ACS Nano"},{"key":"51753_CR40","doi-asserted-by":"crossref","unstructured":"Chang, T. C. et al. Metabolic reprogramming in response to alterations of mitochondrial DNA and mitochondrial dysfunction in gastric adenocarcinoma. Int. J. Mol. Sci. 23(3), 1857 (2022).","DOI":"10.3390\/ijms23031857"},{"issue":"2","key":"51753_CR41","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41419-021-03505-1","volume":"12","author":"X Bao","year":"2021","unstructured":"Bao, X. et al. The crosstalk between HIFs and mitochondrial dysfunctions in cancer development. Cell Death Dis. 12(2), 215 (2021).","journal-title":"Cell Death Dis."},{"issue":"1","key":"51753_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-020-01621-y","volume":"39","author":"Y Cao","year":"2020","unstructured":"Cao, Y., Wang, J., Tian, H. & Fu, G. H. Mitochondrial ROS accumulation inhibiting JAK2\/STAT3 pathway is a critical modulator of CYT997-induced autophagy and apoptosis in gastric cancer. J. Exp. Clin. Cancer Res. 39(1), 119 (2020).","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"51753_CR43","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12967-023-04033-6","volume":"21","author":"J Chang","year":"2023","unstructured":"Chang, J. et al. Constructing a novel mitochondrial-related gene signature for evaluating the tumor immune microenvironment and predicting survival in stomach adenocarcinoma. J. Transl Med. 21 (1), 191 (2023).","journal-title":"J. Transl Med."},{"issue":"4","key":"51753_CR44","first-page":"1671","volume":"39","author":"H Yan","year":"2018","unstructured":"Yan, H. et al. Yap regulates gastric cancer survival and migration via SIRT1\/Mfn2\/mitophagy. Oncol. Rep. 39 (4), 1671\u20131681 (2018).","journal-title":"Oncol. Rep."},{"issue":"1","key":"51753_CR45","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s10549-008-0207-y","volume":"118","author":"K Specht","year":"2009","unstructured":"Specht, K. et al. Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy. Breast Cancer Res. Treat. 118 (1), 45\u201356 (2009).","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"51753_CR46","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.18632\/oncotarget.2645","volume":"6","author":"J Qiao","year":"2015","unstructured":"Qiao, J. et al. Filamin C, a dysregulated protein in cancer revealed by label-free quantitative proteomic analyses of human gastric cancer cells. Oncotarget 6 (2), 1171\u20131189 (2015).","journal-title":"Oncotarget"},{"key":"51753_CR47","doi-asserted-by":"crossref","unstructured":"Dai, P. et al. Unraveling molecular differences of gastric cancer by label-free quantitative proteomics analysis. Int. J. Mol. Sci. 17(1), 69 (2016).","DOI":"10.3390\/ijms17010069"},{"key":"51753_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1707092","volume":"15","author":"B Huang","year":"2025","unstructured":"Huang, B., Yin, Z., Gao, G., Li, L. & Yang, M. DDX49 as a novel prognostic biomarker regulates colorectal cancer cell proliferation through the TIMM44-PI3K-AKT pathway. Front. Oncol. 15, 1707092 (2025).","journal-title":"Front. Oncol."},{"key":"51753_CR49","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2147\/OTT.S189687","volume":"12","author":"Y Liu","year":"2019","unstructured":"Liu, Y. et al. Metabolic reprogramming results in abnormal glycolysis in gastric cancer: A review. Onco Targets Ther. 12, 1195\u20131204 (2019).","journal-title":"Onco Targets Ther."},{"issue":"40","key":"51753_CR50","doi-asserted-by":"publisher","first-page":"68730","DOI":"10.18632\/oncotarget.19612","volume":"8","author":"F Sotgia","year":"2017","unstructured":"Sotgia, F., Fiorillo, M. & Lisanti, M. P. Mitochondrial markers predict recurrence, metastasis and tamoxifen-resistance in breast cancer patients: Early detection of treatment failure with companion diagnostics. Oncotarget 8 (40), 68730\u201368745 (2017).","journal-title":"Oncotarget"},{"issue":"2","key":"51753_CR51","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1136\/gutjnl-2016-311909","volume":"67","author":"Y Huang","year":"2018","unstructured":"Huang, Y. et al. Identification of a fluorescent small-molecule enhancer for therapeutic autophagy in colorectal cancer by targeting mitochondrial protein translocase TIM44. Gut 67 (2), 307\u2013319 (2018).","journal-title":"Gut"},{"issue":"6","key":"51753_CR52","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3892\/ol.2021.12700","volume":"21","author":"H Yang","year":"2021","unstructured":"Yang, H., Li, Y. & Hu, B. Potential role of mitochondria in gastric cancer detection: Fission and glycolysis. Oncol. Lett. 21 (6), 439 (2021).","journal-title":"Oncol. Lett."},{"issue":"3\u20134","key":"51753_CR53","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10495-022-01709-0","volume":"27","author":"P Tanprasert","year":"2022","unstructured":"Tanprasert, P., Limpakan Yamada, S., Chattipakorn, S. C., Chattipakorn, N. & Shinlapawittayatorn, K. Targeting mitochondria as a therapeutic anti-gastric cancer approach. Apoptosis 27 (3\u20134), 163\u2013183 (2022).","journal-title":"Apoptosis"},{"issue":"7","key":"51753_CR54","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","volume":"141","author":"MA Lemmon","year":"2010","unstructured":"Lemmon, M. A. & Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 141 (7), 1117\u20131134 (2010).","journal-title":"Cell"},{"key":"51753_CR55","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.semcancer.2019.03.006","volume":"59","author":"W Jiang","year":"2019","unstructured":"Jiang, W. & Ji, M. Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer. Semin. Cancer Biol. 59, 3\u201322 (2019).","journal-title":"Semin. Cancer Biol."},{"issue":"1","key":"51753_CR56","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/jid.2014.326","volume":"135","author":"YM Zhang","year":"2015","unstructured":"Zhang, Y. M. et al. Requirement of G\u03b1i1\/3-Gab1 signaling complex for keratinocyte growth factor-induced PI3K-AKT-mTORC1 activation. J. Invest. Dermatol. 135(1), 181\u2013191 (2015).","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"51753_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23053-8","volume":"12","author":"W Shi","year":"2021","unstructured":"Shi, W. et al. Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs Trastuzumab sensitivity to gastric cancer. Nat. Commun. 12(1), 2812 (2021).","journal-title":"Nat. Commun."},{"key":"51753_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106610","volume":"187","author":"R Wang","year":"2023","unstructured":"Wang, R. et al. 8-paradol from ginger exacerbates PINK1\/Parkin mediated mitophagy to induce apoptosis in human gastric adenocarcinoma. Pharmacol. Res. 187, 106610 (2023).","journal-title":"Pharmacol. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51753-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51753-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51753-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T02:05:02Z","timestamp":1783303502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51753-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["51753"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-51753-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"assertion":[{"value":"24 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All experiments involving human tissue conducted by this research institute have been approved by the Ethics Committee of the First People\u2019s Hospital of Zhangjiagang City (Ethics Approval No.: 25GYYLL-2022-01-LW004).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"20709"}}